Lv11
70 积分 2024-06-30 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2小时前
待确认
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2小时前
待确认
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
27天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
1个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
1个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
1个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
1个月前
已完结
Review of Drug Safety Data: How to Analyze, Summarize, and Interpret to Determine Risk
2个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
3个月前
已完结
皖公网安备34019202002308
